LADENBURG THALM/SH SH Reaffirms Buy Rating for TG Therapeutics (NASDAQ:TGTX)

LADENBURG THALM/SH SH reiterated their buy rating on shares of TG Therapeutics (NASDAQ:TGTX) in a research report released on Thursday morning, Benzinga reports. The firm currently has a $39.00 target price on the biopharmaceutical company’s stock.

A number of other brokerages have also recently commented on TGTX. The Goldman Sachs Group upped their price target on TG Therapeutics from $12.00 to $13.00 and gave the company a neutral rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. reaffirmed an overweight rating and set a $25.00 price target on shares of TG Therapeutics in a research report on Thursday. StockNews.com cut TG Therapeutics from a buy rating to a hold rating in a research report on Saturday, February 24th. HC Wainwright reissued a buy rating and set a $45.00 price objective on shares of TG Therapeutics in a report on Thursday. Finally, B. Riley increased their price objective on TG Therapeutics from $24.00 to $29.00 and gave the stock a buy rating in a report on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $29.00.

TG Therapeutics Stock Up 1.2 %

Shares of NASDAQ:TGTX opened at $13.99 on Thursday. The company has a market capitalization of $2.16 billion, a PE ratio of 699.85 and a beta of 2.30. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18. The business has a fifty day moving average price of $15.13 and a two-hundred day moving average price of $13.87. TG Therapeutics has a 1 year low of $6.46 and a 1 year high of $35.67.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. The firm had revenue of $43.97 million during the quarter, compared to the consensus estimate of $40.06 million. During the same quarter in the prior year, the company earned ($0.39) EPS. Analysts forecast that TG Therapeutics will post -0.12 earnings per share for the current year.

Insider Buying and Selling

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total value of $351,340.00. Following the sale, the director now owns 215,229 shares of the company’s stock, valued at approximately $3,437,207.13. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 9.20% of the stock is currently owned by insiders.

Institutional Trading of TG Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Pingora Partners LLC purchased a new stake in shares of TG Therapeutics in the 4th quarter valued at about $27,000. PNC Financial Services Group Inc. raised its holdings in shares of TG Therapeutics by 131.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,014 shares in the last quarter. Macquarie Group Ltd. raised its holdings in shares of TG Therapeutics by 102.3% in the 2nd quarter. Macquarie Group Ltd. now owns 10,190 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 5,152 shares in the last quarter. Coppell Advisory Solutions LLC purchased a new stake in shares of TG Therapeutics in the 2nd quarter valued at about $46,000. Finally, KBC Group NV purchased a new stake in shares of TG Therapeutics in the 4th quarter valued at about $54,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.